Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/zaUea4YoC6Q/256854.php
Tuesday, 26 February 2013
Phase III Results: Tiotropium Respimat� Is Effective In Symptomatic Asthma Patients Irrespective Of Their Allergic Status
New Phase III data presented for the first time at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting Tiotropium delivered once daily via Respimat? significantly improved lung function and reduced asthma exacerbations in patients who remain symptomatic despite treatment with at least ICS[1]/LABA[2], irrespective of their allergic status...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment